Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Jul 1;3(4):964-70.
doi: 10.1177/193229680900300445.

Gastric electrical stimulation with the TANTALUS System in obese type 2 diabetes patients: effect on weight and glycemic control

Claudia P Sanmiguel  1 , Jeffrey L Conklin, Scott A Cunneen, Philip Barnett, Edward H Phillips, Mark Kipnes, John Pilcher, Edy E Soffer
Affiliations
Clinical Trial

Gastric electrical stimulation with the TANTALUS System in obese type 2 diabetes patients: effect on weight and glycemic control

Claudia P Sanmiguel et al. J Diabetes Sci Technol. .

Abstract

Background: The TANTALUS System is an investigational device that consists of an implantable pulse generator connected to gastric electrodes. The system is designed to automatically detect when eating starts and only then deliver sessions of gastric electrical stimulation (GES) with electrical pulses that are synchronized to the intrinsic antral slow waves. We report the effect of this type of GES on weight loss and glucose control in overweight/obese subjects with type 2 diabetes mellitus (T2DM). This study was conducted under a Food and Drug Administration/Institutional Review Board-approved investigational device exemption.

Method: Fourteen obese T2DM subjects on oral antidiabetes medication were enrolled and implanted laparoscopically with the TANTALUS System (body mass index 39 +/- 1 kg/m(2), hemoglobin A1c [HbA1c] 8.5 +/- 0.2%).Gastric electrical stimulation was initiated four weeks after implantation. Weight, HbA1c, fasting blood glucose, blood pressure, and lipid levels were assessed during the study period.

Results: Eleven subjects reached the 6-month treatment period endpoint. Gastric electrical stimulation was well tolerated by all subjects. In those patients completing 6 months of therapy, HbA1c was reduced significantly from 8.5 +/- 0.7% to 7.6 +/- 1%, p < .01. Weight was also significantly reduced from 107.7 +/- 21.1 to 102.4 +/- 20.5 kg, p < .01. The improvement in glucose control did not correlate with weight loss (R(2) = 0.05, p = .44). A significant improvement was noted in blood pressure, triglycerides, and cholesterol (low-density lipoprotein only).

Conclusions: Short-term therapy with the TANTALUS System improves glucose control, induces weight loss, and improves blood pressure and lipids in obese T2DM subjects on oral antidiabetes therapy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Effect of GCM on HbA1c levels. This bar chart shows HbA1c levels at different times: enrollment, time 0 (initiation of GCM therapy), and 3 and 6 months of therapy. There was a significant and sustained drop in HbA1c at 3 and 6 months when compared to enrollment. Data are shown as mean ± standard deviation. At 3 and 6 months, p < .05 when compared to enrollment.
Figure 2.
Figure 2.
Effect of GCM on body weight. This bar chart depicts body weight in kilograms at different times during the study. There is a significant reduction in body weight at 3 and 6 months of GCM therapy when compared to enrollment. There is also a significant weight loss at 6 months of GCM therapy when compared to the initiation of the treatment or time 0. Data are shown as mean ± standard deviation. At 3 and 6 months, p < .05 when compared to enrollment. At 6 months, p < .01 when compared to time 0.
See this image and copyright information in PMC

References

    1. National Center for Health Statistics. Data on the prevalence of overweight and obesity among adults: United States. www.cdc.gov/nchs/fastats/overwt.htm.
    1. National Center for Health Statistics. Prevalence of overweight among children and adolescents: United States, 1999–2002. www.cdc.gov/nchs/products/pubs/pubd/hestats/overwght99.htm.
    1. Ogden CL, Carroll MD, Flegal KM. Epidemiologic trends in overweight and obesity. Endocrinol Metabl Clin North Am. 2003;32(4):741–760. - PubMed
    1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053. - PubMed
    1. Hogan P, Dall T, Nikolov P. American Diabetes Association. Economic costs of diabetes in US in 2002. Diabetes Care. 2003;26(3):917–932. - PubMed

Publication types

MeSH terms